27 results on '"Mannis G"'
Search Results
2. Advance care planning and end-of-life care for patients with hematologic malignancies who die after hematopoietic cell transplant
- Author
-
Eckhert, E E, Schoenbeck, K L, Galligan, D, McNey, L M, Hwang, J, and Mannis, G N
- Published
- 2017
- Full Text
- View/download PDF
3. P514: V-FAST MASTER TRIAL: PRELIMINARY RESULTS OF TREATMENT WITH CPX-351 PLUS MIDOSTAURIN IN ADULTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA
- Author
-
McCloskey, J., primary, Pullarkat, V., additional, Mannis, G., additional, Lin, T. L., additional, Strickland, S. A., additional, Fathi, A. T., additional, Erba, H. P., additional, Faderl, S., additional, Chakravarthy, D., additional, Lutska, Y., additional, Chandrasekaran, V., additional, Cheung, R. S., additional, and Levis, M., additional
- Published
- 2022
- Full Text
- View/download PDF
4. S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS
- Author
-
Daver, N. G., primary, Vyas, P., additional, Kambhampati, S., additional, Al Malki, M. M., additional, Larson, R., additional, Asch, A., additional, Mannis, G., additional, Chai-Ho, W., additional, Tanaka, T., additional, Bradley, T., additional, Jeyakumar, D., additional, Wang, E., additional, Xing, G., additional, Chao, M., additional, Ramsingh, G., additional, Renard, C., additional, Lal, I., additional, Zeidner, J., additional, and Sallman, D., additional
- Published
- 2022
- Full Text
- View/download PDF
5. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis
- Author
-
Mannis, G N, Logan, A C, Leavitt, A D, Yanada, M, Hwang, J, Olin, R L, Damon, L E, Andreadis, C, Ai, W Z, Gaensler, K M, Greene, C C, Gupta, N K, Kaplan, L D, Mahindra, A, Miyazaki, Y, Naoe, T, Ohtake, S, Sayre, P H, Smith, C C, Venstrom, J M, Wolf, J L, Caballero, L, Emi, N, and Martin, T G
- Published
- 2015
- Full Text
- View/download PDF
6. The first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results
- Author
-
Sallman, D, Asch, A, Kambhampati, S, Al Malki, M, Zeidner, J, Donnellan, W, Lee, D, Vyas, P, Jeyakumar, D, Mannis, G, Tanaka, T, Chai-Ho, W, Larson, R, Whiteley, A, Marcucci, G, Komrokji, R, Garcia-Manero, G, Van Elk, J, Lin, M, Maute, R, Volkmer, J-P, Takimoto, C, Chao, M, and Daver, N
- Published
- 2021
7. Maintenance lenalidomide in primary CNS lymphoma
- Author
-
Rubenstein, J.L., primary, Geng, H., additional, Vu, K., additional, Mannis, G., additional, Formaker, P., additional, Hwang, J., additional, Munster, P.N., additional, and Damato, B., additional
- Published
- 2019
- Full Text
- View/download PDF
8. Preliminary analysis of lenalidomide maintenance after methotrexate-temozolomide-rituximab induction in older patients with PCNSL
- Author
-
Rubenstein, J.L., primary, Hwang, J., additional, and Mannis, G., additional
- Published
- 2017
- Full Text
- View/download PDF
9. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis
- Author
-
Mannis, G N, primary, Logan, A C, additional, Leavitt, A D, additional, Yanada, M, additional, Hwang, J, additional, Olin, R L, additional, Damon, L E, additional, Andreadis, C, additional, Ai, W Z, additional, Gaensler, K M, additional, Greene, C C, additional, Gupta, N K, additional, Kaplan, L D, additional, Mahindra, A, additional, Miyazaki, Y, additional, Naoe, T, additional, Ohtake, S, additional, Sayre, P H, additional, Smith, C C, additional, Venstrom, J M, additional, Wolf, J L, additional, Caballero, L, additional, Emi, N, additional, and Martin, T G, additional
- Published
- 2014
- Full Text
- View/download PDF
10. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
- Author
-
DiNardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., Swords, R., Collins, R. H., Mannis, G. N., Pollyea, D. A., Donnellan, W., Fathi, A. T., Pigneux, A., Erba, H. P., Prince, G. T., Stein, A. S., Uy, G. L., Foran, J. M., Traer, E., and Stuart, R. K.
- Subjects
- *
GENETIC mutation , *ISOCITRATE dehydrogenase , *ACUTE myeloid leukemia , *SMALL molecules , *DRUG dosage , *DRUG efficacy , *DISEASE remission , *CANCER relapse , *CLINICAL trials , *COMPARATIVE studies , *DRUG resistance in cancer cells , *DOSE-effect relationship in pharmacology , *ENZYME inhibitors , *HEMOGLOBINS , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *ORAL drug administration , *OXIDOREDUCTASES , *RESEARCH , *SURVIVAL , *DISEASE relapse , *CYTOMETRY , *EVALUATION research , *CHEMICAL inhibitors - Abstract
Background: Mutations in the gene encoding isocitrate dehydrogenase 1 ( IDH1) occur in 6 to 10% of patients with acute myeloid leukemia (AML). Ivosidenib (AG-120) is an oral, targeted, small-molecule inhibitor of mutant IDH1.Methods: We conducted a phase 1 dose-escalation and dose-expansion study of ivosidenib monotherapy in IDH1-mutated AML. Safety and efficacy were assessed in all treated patients. The primary efficacy population included patients with relapsed or refractory AML receiving 500 mg of ivosidenib daily with at least 6 months of follow-up.Results: Overall, 258 patients received ivosidenib and had safety outcomes assessed. Among patients with relapsed or refractory AML (179 patients), treatment-related adverse events of grade 3 or higher that occurred in at least 3 patients were prolongation of the QT interval (in 7.8% of the patients), the IDH differentiation syndrome (in 3.9%), anemia (in 2.2%), thrombocytopenia or a decrease in the platelet count (in 3.4%), and leukocytosis (in 1.7%). In the primary efficacy population (125 patients), the rate of complete remission or complete remission with partial hematologic recovery was 30.4% (95% confidence interval [CI], 22.5 to 39.3), the rate of complete remission was 21.6% (95% CI, 14.7 to 29.8), and the overall response rate was 41.6% (95% CI, 32.9 to 50.8). The median durations of these responses were 8.2 months (95% CI, 5.5 to 12.0), 9.3 months (95% CI, 5.6 to 18.3), and 6.5 months (95% CI, 4.6 to 9.3), respectively. Transfusion independence was attained in 29 of 84 patients (35%), and patients who had a response had fewer infections and febrile neutropenia episodes than those who did not have a response. Among 34 patients who had a complete remission or complete remission with partial hematologic recovery, 7 (21%) had no residual detectable IDH1 mutations on digital polymerase-chain-reaction assay. No preexisting co-occurring single gene mutation predicted clinical response or resistance to treatment.Conclusions: In patients with advanced IDH1-mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment-related adverse events and with transfusion independence, durable remissions, and molecular remissions in some patients with complete remission. (Funded by Agios Pharmaceuticals; ClinicalTrials.gov number, NCT02074839 .). [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
11. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
- Author
-
Pemmaraju N, Madanat YF, Rizzieri D, Fazal S, Rampal R, Mannis G, Wang ES, Foran J, and Lane AA
- Subjects
- Humans, Treatment Outcome, Interleukin-3 Receptor alpha Subunit metabolism, Interleukin-3 Receptor alpha Subunit analysis, Hematologic Neoplasms therapy, Hematologic Neoplasms pathology, Hematologic Neoplasms diagnosis, Disease Management, Myeloproliferative Disorders diagnosis, Myeloproliferative Disorders therapy, Myeloproliferative Disorders pathology, Recombinant Fusion Proteins therapeutic use, Prognosis, Dendritic Cells
- Abstract
BPDCN is an aggressive myeloid malignancy with a poor prognosis. It derives from the precursors of plasmacytoid dendritic cells and is characterized by CD123 overexpression, which is seen in all patients with BPDCN. The CD123-directed therapy tagraxofusp is the only approved treatment for BPDCN; it was approved in the US as monotherapy for the treatment of patients aged ≥2 years with treatment-naive or relapsed/refractory BPDCN. Herein, we review the available data supporting the utility of tagraxofusp in treating patients with BPDCN. In addition, we present best practices and real-world insights from clinicians in academic and community settings in the US on how they use tagraxofusp to treat BPDCN. Several case studies illustrate the efficacy of tagraxofusp and discuss its safety profile, as well as the prevention, mitigation, and management of anticipated adverse events.
- Published
- 2024
- Full Text
- View/download PDF
12. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.
- Author
-
Gaut D, Oliai C, Boiarsky J, Zhang S, Salhotra A, Azenkot T, Kennedy VE, Khanna V, Olmedo Gutierrez K, Shukla N, Moskoff B, Park G, Afkhami M, Patel A, Jeyakumar D, Mannis G, Logan AC, Jonas BA, and Schiller G
- Subjects
- Humans, Consolidation Chemotherapy, Retrospective Studies, Remission Induction, Cytarabine, Neoplasm, Residual diagnosis, Prognosis, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute drug therapy, Hematopoietic Stem Cell Transplantation
- Abstract
The rate of MRD clearance in AML with standard consolidation chemotherapy is not well defined. A multi-institution retrospective analysis was performed on 107 consecutively treated AML patients in morphologic complete remission with detectable MRD post-induction therapy who received standard chemotherapy consolidation. In response to standard intermediate/high-dose cytarabine consolidation therapy, 26 of 60 patients (43.3%) with MRD threshold of detection of at least 0.1% converted to MRD-negative status (undetectable with assay used), and 6 of 47 patients (12.8%) with MRD threshold of detection > 0.1% converted to MRD-negative status. Multivariable logistic regression for patients with MRD threshold of detection of at least 0.1% showed that, when controlling for age, ELN risk category, dose of cytarabine, and use of a combination agent, treatment with 1 cycle of consolidation cytarabine versus ≥2 cycles decreased the odds of conversion of AML to MRD-negative (OR = 0.24, 95% CI 0.07-0.85, p = 0.03).
- Published
- 2024
- Full Text
- View/download PDF
13. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.
- Author
-
Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, Mannis G, Chai-Ho W, Tanaka TN, Bradley TJ, Jeyakumar D, Wang ES, Sweet K, Kantarjian HM, Garcia-Manero G, Komrokji R, Xing G, Ramsingh G, Renard C, Zeidner JF, and Sallman DA
- Subjects
- Humans, Antibodies, Monoclonal, Humanized therapeutic use, Remission Induction, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Azacitidine, Leukemia, Myeloid, Acute drug therapy
- Abstract
Purpose: Magrolimab is a first-in-class humanized monoclonal antibody against cluster of differentiation 47, an antiphagocytic signal used by cancer cells to evade phagocytosis. Azacitidine upregulates prophagocytic signals on AML cells, further increasing phagocytosis when combined with magrolimab. We report final phase Ib data for magrolimab with azacitidine in patients with untreated AML ineligible for intensive chemotherapy (ClinicalTrials.gov identifier: NCT03248479)., Patients and Methods: Patients with previously untreated AML, including TP53 -mutant AML, received magrolimab intravenously as an initial dose (1 mg/kg, days 1 and 4), followed by 15 mg/kg once on day 8 and 30 mg/kg once weekly or every 2 weeks as maintenance. Azacitidine 75 mg/m
2 was administered intravenously/subcutaneously once daily on days 1-7 of each 28-day cycle. Primary end points were safety/tolerability and proportion with complete remission (CR)., Results: Eighty-seven patients were enrolled and treated; 72 (82.8%) had TP53 mutations with a median variant allele frequency of 61% (range, 9.8-98.7). Fifty-seven (79.2%) of TP53 -mutant patients had European LeukemiaNet 2017 adverse-risk cytogenetics. Patients received a median of 4 (range, 1-39) cycles of treatment. The most common treatment-emergent adverse events included constipation (49.4%), nausea (49.4%), and diarrhea (48.3%). Thirty (34.5%) experienced anemia, and the median hemoglobin change from baseline to first postdose assessment was -0.9 g/dL (range, -3.6 to 2.5 g/dL). Twenty-eight (32.2%) patients achieved CR, including 23 (31.9%) patients with TP53 mutations. The median overall survival in TP53- mutant and wild-type patients were 9.8 months and 18.9 months, respectively., Conclusion: Magrolimab with azacitidine was relatively well tolerated with promising efficacy in patients with AML ineligible for intensive induction chemotherapy, including those with TP53 mutations, warranting further evaluation of magrolimab with azacitidine in AML. The phase III randomized ENHANCE-2 (ClinicalTrials.gov identifier: NCT04778397) and ENHANCE-3 (ClinicalTrials.gov identifier: NCT05079230) studies are recruiting frontline patients with AML.- Published
- 2023
- Full Text
- View/download PDF
14. Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician.
- Author
-
Lai C, Bhansali RS, Kuo EJ, Mannis G, and Lin RJ
- Subjects
- Humans, Aged, Anthracyclines therapeutic use, Cytarabine therapeutic use, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute therapy
- Abstract
Over the past decade, our understanding of AML pathogenesis and pathophysiology has improved significantly with mutational profiling. This has led to translational advances in therapeutic options, as there have been 10 new US Food and Drug Administration (FDA) approvals for AML therapies since 2017, half of which target specific driver mutations in FLT3 , IDH1 , or IDH2 . These new agents have expanded the therapeutic armamentarium for AML, particularly for patients who are considered ineligible for intensive chemotherapy with anthracycline- and cytarabine-containing regimens. These new treatment options are relevant because the median age at diagnosis is 68 years, and outcomes for patients older than 60 years have historically been dismal. However, the optimal approach to incorporating novel agents into frontline regimens remains a clinical challenge, particularly with regard to sequencing of therapies, considering the role of allogeneic hematopoietic stem cell transplantation and managing toxicities.
- Published
- 2023
- Full Text
- View/download PDF
15. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
- Author
-
Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, and Stehman K
- Subjects
- Adult, Humans, Dendritic Cells pathology, Medical Oncology, Hematologic Neoplasms diagnosis, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute therapy, Leukemia, Myeloid, Acute pathology, Skin Neoplasms diagnosis
- Abstract
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States. Like AML, blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a myeloid malignancy. It is a rare malignancy characterized by the aggressive proliferation of precursors of plasmacytoid dendritic cells that frequently involves the bone marrow, skin, central nervous system, and other organs and tissues. This discussion section focuses on the diagnosis and management of BPDCN as outlined in the NCCN Guidelines for AML.
- Published
- 2023
- Full Text
- View/download PDF
16. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
- Author
-
Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson NR, Konopleva M, Frankel AE, Gupta V, Mesa R, Ulrickson M, Gorak E, Bhatia S, Budak-Alpdogan T, Mason J, Garcia-Romero MT, Lopez-Santiago N, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran J, Fathi AT, Hall AC, Jacoby MA, Lancet J, Mannis G, Stein AS, Mims A, Rizzieri D, Olin R, Perl A, Schiller G, Shami P, Stone RM, Strickland S, Wieduwilt MJ, Daver N, Ravandi F, Vasu S, Guzman M, Roboz GJ, Khoury J, Qazilbash M, Aung PP, Cuglievan B, Madanat Y, Kharfan-Dabaja MA, Pawlowska A, Taylor J, Tallman M, Dhakal P, and Lane AA
- Subjects
- Child, Humans, Aged, Standard of Care, Interleukin-3 Receptor alpha Subunit, Dendritic Cells pathology, Neoplasm Recurrence, Local pathology, Acute Disease, North America, Myeloproliferative Disorders pathology, Hematologic Neoplasms pathology, Skin Neoplasms pathology
- Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous involvement, BPDCN can also invade other extramedullary compartments, including the central nervous system. Generally affecting older adults, many patients are unfit to receive intensive chemotherapy, and although hematopoietic stem cell transplantation is preferred for younger, fit individuals, not all are eligible. One recent therapeutic breakthrough is that all BPDCNs express CD123 (IL3Rα) and that this accessible surface marker can be pharmacologically targeted. The first-in-class agent for BPDCN, tagraxofusp, which targets CD123, was approved in December 2018 in the United States for patients with BPDCN aged ≥2 years. Despite favorable response rates in the frontline setting, many patients still relapse in the setting of monotherapy, and outcomes in patients with relapsed/refractory BPDCN remain dismal. Therefore, novel approaches targeting both CD123 and other targets are actively being investigated. To begin to formally address the state of the field, we formed a new collaborative initiative, the North American BPDCN Consortium (NABC). This group of experts, which includes a multidisciplinary panel of hematologists/oncologists, hematopoietic stem cell transplant physicians, pathologists, dermatologists, and pediatric oncologists, was tasked with defining the current standard of care in the field and identifying the most important research questions and future directions in BPDCN. The position findings of the NABC's inaugural meetings are presented herein., (© 2023 by The American Society of Hematology.)
- Published
- 2023
- Full Text
- View/download PDF
17. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.
- Author
-
On S, Rath CG, Lan M, Wu B, Lau KM, Cheung E, Alegria W, Young R, Tan M, Kim C, Phun J, Patel N, Mannis G, Logan AC, Kennedy V, Goodman A, Taplitz RA, Young PA, Wen R, and Saunders IM
- Subjects
- Adult, Antifungal Agents therapeutic use, Bridged Bicyclo Compounds, Heterocyclic, Cohort Studies, Humans, Retrospective Studies, Sulfonamides, Invasive Fungal Infections epidemiology, Leukemia, Myeloid, Acute complications
- Abstract
We investigated the incidence of invasive fungal infections (IFIs) and other infectious complications in patients receiving venetoclax and hypomethylating agent therapy for acute myeloid leukaemia (AML). This retrospective, multicentre cohort study included adult patients with AML who received at least one cycle of venetoclax and either azacitidine or decitabine between January 2016 and August 2020. The primary outcome was the incidence of probable or confirmed IFI. Secondary outcomes included antifungal prophylaxis prescribing patterns, incidence of bacterial infections, and incidence of neutropenic fever hospital admissions. Among 235 patients, the incidence of probable or confirmed IFI was 5.1%. IFI incidence did not differ significantly according to age, antifungal prophylaxis use, or disease status. In the subgroup of patients with probable or confirmed IFIs, six (50%) were receiving antifungal prophylaxis at the time of infection. The overall incidence of developing at least one bacterial infection was 33.6% and 127 (54%) patients had at least one hospital admission for febrile neutropenia. This study demonstrated an overall low risk of developing probable or confirmed IFI as well as a notable percentage of documented bacterial infections and hospital admissions due to neutropenic fever., (© 2022 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
18. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
- Author
-
Numan Y, Abdel Rahman Z, Grenet J, Boisclair S, Bewersdorf JP, Collins C, Barth D, Fraga M, Bixby DL, Zeidan AM, Yilmaz M, Desai P, Mannis G, Deutsch YE, Abaza Y, Dinner S, Frankfurt O, Litzow M, Al-Kali A, Foran JM, Sproat LZ, Jovanovic B, Daver N, Perl AE, and Altman JK
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Humans, Male, Middle Aged, Recurrence, Retrospective Studies, Staurosporine administration & dosage, Survival Rate, Aniline Compounds administration & dosage, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute enzymology, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute mortality, Mutation, Pyrazines administration & dosage, Staurosporine analogs & derivatives, fms-Like Tyrosine Kinase 3 antagonists & inhibitors, fms-Like Tyrosine Kinase 3 genetics
- Abstract
Gilteritinib is approved for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with an FLT3-mutation (FLT3
mut+ ). However, the gilteritinib phase 3 ADMIRAL study (Perl et al NEJM 2019) was conducted prior to widespread adoption of either midostaurin as a component of standard intensive induction and consolidation or posttransplant FLT3 inhibitor maintenance. We performed a retrospective analysis using data from 11 US centers and where we identified 113 patients who received gilteritinib alone or as combination therapy for the treatment of R/R FLT3mut+ AML. The composite complete remission (CR) rate (CRc, defined as CR + CRi + CR with incomplete platelet recovery [CRp]) was 48.7% (n = 55). The CRc rate after treatment with gilteritinib in patients who were treated with only prior 7+3 and midostaurin with or without consolidation was 58% with a median survival of 7.8 months. Survival was longest in patients who obtained a CR, particularly a cMRD (clinical minimal or measurable residual disease) negative response; this remained significant after censoring at the time of stem cell transplant. The mitogen-activated protein kinase pathway activating mutations that are known for gilteritinib resistance (NRAS, KRAS, and PTPN11) had lower CRc (35% vs. 60.5%) and lower median overall survival than patients' whose leukemia did not express these mutations (4.9 months vs. 7.8 months) (HR 2.4; 95% CI 1. 5.4) p value <.01., (© 2022 Wiley Periodicals LLC.)- Published
- 2022
- Full Text
- View/download PDF
19. Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin.
- Author
-
Ladha A, Mannis G, and Muffly L
- Subjects
- Gemtuzumab, Humans, Inotuzumab Ozogamicin, Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation adverse effects, Hepatic Veno-Occlusive Disease chemically induced, Hepatic Veno-Occlusive Disease diagnosis
- Abstract
Hepatic veno-occlusive disease (VOD/sinusoidal obstructive syndrome) represents a constellation of clinical findings including right upper quadrant pain, jaundice, hepatomegaly, and ascites. In the post-hematopoietic stem cell transplant (SCT) setting, the reported incidence has been 10-15%, with severe VOD historically resulting in high mortality rates. Novel agents including calicheamicin conjugated with CD33 (gemtuzumab ozogamicin; GO) and CD22 (inotuzumab ozogamicin; InO) are increasingly used for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia, respectively. Both GO and InO are highly active, but also have unique hepatotoxicity profiles, including a higher risk of VOD in recipients of SCT. Introduction of GO and InO into pre-SCT leukemia management adds additional complexity to SCT patient selection and toxicity monitoring. In this article, we describe and review the risks and management associated with VOD in SCT recipients exposed to GO and InO.
- Published
- 2021
- Full Text
- View/download PDF
20. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
- Author
-
Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J, Nejati R, Olin R, Percival ME, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ, Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, and Tallman MS
- Subjects
- Adult, Humans, Mutation, Prognosis, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute therapy
- Abstract
The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.
- Published
- 2021
- Full Text
- View/download PDF
21. Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy.
- Author
-
Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, Ciurea SO, Holtzman NG, Ii GLP, Devine SM, Mannis G, Grunwald MR, Appelbaum F, Rodriguez C, El Chaer F, Shah N, Hashmi SK, Kharfan-Dabaja MA, DeFilipp Z, Aljurf M, AlShaibani A, Inamoto Y, Jain T, Majhail N, Perales MA, Mohty M, Hamadani M, Carpenter PA, and Nagler A
- Subjects
- Adult, Humans, Transplantation Conditioning, Transplantation, Homologous, United States, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute therapy
- Abstract
The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and nontransplant experts, was invited to develop clinically relevant frequently asked questions covering disease- and HCT-related topics. A systematic literature review was conducted to generate core recommendations that were graded based on the quality and strength of underlying evidence based on the standardized criteria established by the American Society of Transplantation and Cellular Therapy Steering Committee for evidence-based reviews. Allogeneic HCT offers a survival benefit in patients with intermediate- and high-risk AML and is currently a part of standard clinical care. We recommend the preferential use of myeloablative conditioning in eligible patients. A haploidentical related donor marrow graft is preferred over a cord blood unit in the absence of a fully HLA-matched donor. The evolving role of allogeneic HCT in the context of measurable residual disease monitoring and recent therapeutic advances in AML with regards to maintenance therapy after HCT are also discussed., (Copyright © 2020 The American Society for Transplantation and Cellular Therapy. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
22. Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
- Author
-
Azizi A, Ediriwickrema A, Dutta R, Patel SA, Shomali W, Medeiros B, Iberri D, Gotlib J, Mannis G, Greenberg P, Majeti R, and Zhang T
- Subjects
- Azacitidine adverse effects, Bridged Bicyclo Compounds, Heterocyclic, Decitabine, Humans, Retrospective Studies, Sulfonamides, Treatment Outcome, Myelodysplastic Syndromes drug therapy
- Abstract
Treatment with hypomethylating agents (HMAs) azacitidine or decitabine is the current standard of care for high risk myelodysplastic syndromes (MDSs) but is associated with low rates of response. The limited number of treatment options for patients with high risk MDS highlights a need for new therapeutic options. Venetoclax is an inhibitor of the BCL-2 protein which, when combined with an HMA, has shown high response rates in unfit and previously untreated acute myeloid leukemia. We performed a retrospective study of high risk MDS patients receiving combination HMA plus venetoclax in order to determine their effectiveness in this context. We show that in our cohort, the combination results in high response rates but is associated with a high frequency of myelosuppression. These data highlight the efficacy of combination HMA plus venetoclax in high risk MDS, warranting further prospective evaluation in clinical trials.
- Published
- 2020
- Full Text
- View/download PDF
23. Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.
- Author
-
Vu K, Mannis G, Hwang J, Geng H, and Rubenstein JL
- Subjects
- Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Induction Chemotherapy, Male, Treatment Outcome, Central Nervous System Neoplasms drug therapy, Lenalidomide administration & dosage, Lymphoma, Non-Hodgkin drug therapy
- Published
- 2019
- Full Text
- View/download PDF
24. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
- Author
-
Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM, Hammond L, and Ogba N
- Subjects
- Age Factors, Aged, Antineoplastic Combined Chemotherapy Protocols standards, Biomarkers, Tumor genetics, Biomarkers, Tumor immunology, Cytogenetic Analysis standards, Disease-Free Survival, Graft vs Host Disease immunology, Graft vs Host Disease prevention & control, HLA Antigens immunology, Hematopoietic Stem Cell Transplantation adverse effects, Histocompatibility Testing standards, Humans, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute mortality, Middle Aged, Remission Induction methods, Risk Assessment standards, Transplantation, Homologous adverse effects, United States, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor analysis, Hematopoietic Stem Cell Transplantation standards, Leukemia, Myeloid, Acute therapy, Medical Oncology standards
- Abstract
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.
- Published
- 2019
- Full Text
- View/download PDF
25. Long-term survival in AIDS-related primary central nervous system lymphoma.
- Author
-
Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, and Rubenstein JL
- Subjects
- Adult, Aged, Antimetabolites, Antineoplastic therapeutic use, Central Nervous System Neoplasms pathology, Central Nervous System Neoplasms therapy, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Lymphoma, AIDS-Related pathology, Lymphoma, AIDS-Related therapy, Male, Middle Aged, Neoplasm Staging, Prognosis, Retrospective Studies, Survival Rate, Anti-Retroviral Agents therapeutic use, Central Nervous System Neoplasms mortality, Cranial Irradiation, Lymphoma, AIDS-Related mortality, Methotrexate therapeutic use
- Abstract
Background: The optimal therapeutic approach for patients with AIDS-related primary central nervous system lymphoma (AR-PCNSL) remains undefined. While its incidence declined substantially with combination antiretroviral therapy (cART), AR-PCNSL remains a highly aggressive neoplasm for which whole brain radiotherapy (WBRT) is considered a standard first-line intervention., Methods: To identify therapy-related factors associated with favorable survival, we first retrospectively analyzed outcomes of AR-PCNSL patients treated at San Francisco General Hospital, a public hospital with a long history of dedicated care for patients with HIV and AIDS-related malignancies. Results were validated in a retrospective, multicenter analysis that evaluated all newly diagnosed patients with AR-PCNSL treated with cART plus high-dose methotrexate (HD-MTX)., Results: We provide evidence that CD4+ reconstitution with cART administered during HD-MTX correlates with long-term survival among patients with CD4 <100. This was confirmed in a multicenter analysis which demonstrated that integration of cART regimens with HD-MTX was generally well tolerated and resulted in longer progression-free survival than other treatments. No profound differences in immunophenotype were identified in an analysis of AR-PCNSL tumors that arose in the pre- versus post-cART eras. However, we detected evidence for a demographic shift, as the proportion of minority patients with AR-PCNSL increased since advent of cART., Conclusion: Long-term disease-free survival can be achieved in AR-PCNSL, even among those with histories of opportunistic infections, limited access to health care, and medical non-adherence. Given this, as well as the long-term toxicities of WBRT, we recommend that integration of cART plus first-line HD-MTX be considered for all patients with AR-PCNSL., (© The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
26. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
- Author
-
Mannis G, Wu D, Dea T, Mauro T, and Hsu G
- Subjects
- Adenine analogs & derivatives, Aged, Allopurinol therapeutic use, Antimetabolites therapeutic use, Antineoplastic Agents administration & dosage, Chromosomes, Human, Pair 17, Exanthema pathology, Humans, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Male, Piperidines, Pyrazoles administration & dosage, Pyrimidines administration & dosage, Smith-Magenis Syndrome, Antineoplastic Agents adverse effects, Chromosome Deletion, Exanthema chemically induced, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Pyrazoles adverse effects, Pyrimidines adverse effects
- Published
- 2015
- Full Text
- View/download PDF
27. [Anthropometric study of 22 measurements of dental arches, using computers].
- Author
-
Zanetti AL, Froner EE, Mannis G, and Fukumasu M
- Subjects
- Computers, Humans, Models, Dental, Anthropometry, Dental Arch anatomy & histology
- Published
- 1977
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.